I-Global Osteogenesis Osteogenesis Imperfecta Treatment Market, NgeMizila Yokulethwa Kwezidakamizwa nangeSifunda: Usayizi, Ukwabelana, Ukuhlaziywa Kwe-Outlook kanye Namathuba, 2023 – 2030

I-Osteogenesis imperfecta yisifo sofuzo esithinta amathambo futhi sivimbela umzimba ekwakheni amathambo aqinile.

Lesi sifo senza amathambo abe brittle futhi aphuke kalula ngaphandle kwesizathu.

I-Osteogenesis Imperfecta ibizwa ngokuthi ukwakheka kwamathambo okungaphelele, futhi abantu abaphethwe yilesi sifo banamathambo aphuka noma aphuka kalula.

Introduzione

I-Osteogenesis Imperfecta ivame ukubizwa ngokuthi yi-brittle bone disease. Ezimweni ezimbi kakhulu, ukuphuka okuningi kuvamile, kuyilapho icala elincane lihilela ukuphuka okumbalwa noma amathambo aphukile empilweni yomuntu. Abantu abanalesi simo bazalwa bengakwazi ukukhiqiza izicubu ezixhumeneyo noma ukuba nazo ngenxa yofuzo olungalungile. Ithinta ukwakheka kwe-collagen, iphrotheni yezicubu ezixhumeneyo eziqinisa amathambo. Lesi sifo sitholakala kumafomu I no-IX, mina ngimnene futhi IX ngibulala. Uphawu oluyinhloko lwe-osteogenesis imperfecta ukuphuka njalo. Ezinye izimpawu zihlanganisa ukuxega kwamalunga, amathambo akhubazekile, ukungezwa, izinkinga zokuphefumula kanye nezinkinga zamazinyo. I-Osteogenesis imperfecta ingaqinisekiswa nge-DNA noma ukuhlolwa kwe-collagen.

ukwelashwa

Akukho ukwelashwa kwalokhu ngoba kuyisimo sofuzo. Ukuzivocavoca nokuyeka ukubhema kuyizibonelo ezimbili zendlela yokuphila enempilo engasiza ekuvimbeleni ukuphuka. Izinsimbi, izidambisa-zinhlungu, nokunakekelwa okufanele kokuphuka kwamathambo konke kuyasiza. Ama-antibiotics kanye nama-antiseptics angasetshenziswa ukwelapha izifo zamathambo. Ukwenyuka kwesidingo sezindlela zokwelapha ezintsha zokwelapha i-osteogenesis imperfecta kanye nezivumelwano zamalayisense nokusebenzisana kwamasu ngabadlali ababalulekile bezimboni zokuthuthukiswa kokwelashwa kulindeleke ukuthi kuqhubekisele phambili ukukhula kwemakethe yokwelashwa kwe-osteogenesis imperfecta yomhlaba wonke esikhathini sokubikezela.

Amandla emakethe

Ukwenyuka kwezimali zocwaningo kanye nentuthuko ukuthuthukisa izindlela zokwelapha ezintsha kanye nokwelapha kuyisici esibalulekile esikhuthaza ukukhula kwemakethe yokwelashwa kwe-osteogenesis imperfecta yomhlaba wonke. Ngaphezu kwalokho, izivumelwano zamalayisense nokusebenzisana kwamasu ngabadlali bemboni abaholayo ekuthuthukisweni kokwelashwa kwe-OI kungenye into eqhuba ukukhula kwemakethe. Ngaphezu kwalokho, i-osteogenesis imperfecta yisifo sofuzo, futhi umlando womndeni wabantu abane-OI ubangela ukwanda kwenani lamacala emhlabeni wonke, okulindeleke ukuthi kuqhubekisele phambili ukukhula kwemakethe.

Isibonelo, ngoMeyi 2021, i-Mereo BioPharma Group plc yamemezela idatha ekhuthazayo yezinyanga eziyisi-6 kusukela ocwaningweni lwayo lomtholampilo lweSigaba II-B ezigulini ezikhulile ezine-osteogenesis imperfecta uhlobo IV, III noma mina ngelashwe nge-setursumab (BPS-804). I-European Medicines Agency (EMA) igunyaze uhlelo lwenkampani lophenyo lwezingane lwe-BPS-804 kanye nedizayini yocwaningo lokubhalisa, futhi umuntu ozongenela umuthi uselungele Isigaba III sezingane.

Izici eziyinhloko zocwaningo:

• Lo mbiko uhlinzeka ngokuhlaziywa okujulile kwemakethe yomhlaba wonke ye-Osteogenesis Imperfecta Treatment futhi uhlinzeka ngosayizi wemakethe (USD Million) kanye neCompound Annual Growth Rate (CAGR%) ngesikhathi sokubikezela (2023-2030), kubhekwa u-2022 njengonyaka oyisisekelo.
• Icacisa amathuba emali engenayo engaba khona ezigabeni ezihlukene futhi ichaza amatrices esiphakamiso sokutshala izimali ezikhangayo kule makethe.
• Lolu cwaningo luphinde lunikeze imininingwane ebalulekile mayelana nezishayeli zemakethe, imikhawulo, amathuba, ukwethulwa kwemikhiqizo emisha noma ukugunyazwa, izitayela zemakethe, umbono wesifunda, namasu okuncintisana atholwe abadlali ababalulekile.
• Amaphrofayili abadlali ababalulekile emakethe yomhlaba wonke ye-Osteogenesis Imperfecta Treatment ngokususelwe kule mingcele elandelayo: Okugqanyisiwe Kwenkampani, Iphothifoliyo Yomkhiqizo, Okugqanyisiwe Okubalulekile, Ukusebenza Kwezezimali, Namasu.
• Izinkampani ezinkulu ezifakwe ngaphansi kwalolu cwaningo yi-BioSenic SA, Mereo Biopharma Group PLC, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Amgen Inc., Sun Pharmaceutical Industries Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd. , Merck & Co., Inc., Jubilant Pharmova Limited, Aurobindo Pharma, Quince, Ultragenyx Pharmaceutical Inc. kanye ne-OrthoPediatrics Corp.
• Imibono evela kulo mbiko izokwenza abakhangisi nabaphathi bezinkampani benze izinqumo ezinolwazi mayelana nokwethulwa kwemikhiqizo yabo esikhathini esizayo, ukuthuthukiswa kohlobo, ukunwetshwa kwemakethe namaqhinga okumaketha.

Umbiko wemakethe ye-Osteogenesis Imperfecta Treatment yomhlaba wonke ukhuluma nababambiqhaza abahlukahlukene kulo mkhakha, okuhlanganisa abatshalizimali, abahlinzeki, abakhiqizi bemikhiqizo, abasabalalisi, abasanda kungena, nabahlaziyi bezezimali:

• Ababambiqhaza bebezokhululeka ekuthatheni izinqumo ngomatikuletsheni bamasu ahlukene asetshenziswa ekuhlaziyeni imakethe yomhlaba wonke ye-Osteogenesis Imperfecta Treatment.

Isegimenti enemininingwane:

I-Global Osteogenesis Imperfecta Treatment Market, ngezidakamizwa:

• I-Teriparatide
• I-Denosumab
• Okunye

ukwelashwa kwe-osteogenesis imperfecta, iMakethe Yomhlaba Wonke ngomzila Wokuphatha:

• I-subcutaneous
• Ngemithambo
• Ngomlomo
• Okunye

I-Global Osteogenesis Imperfecta Treatment Market, Ngesifunda:

• I-North America
• I-United States of America
• Canada
• Latin America
• Brazil
• Mexico
• Argentina
• Yonke indawo yaseLatin America
• Europa
• Germania
• United Kingdom
• EFrance
• Italia
• Spain
• Russia
• I-Europe yonke
• I-Asia Pacific
• China
• India
• Japan
• Australia
• ENingizimu Korea
• I-ASEAN
• Indawo yonke yase-Asia Pacific
• Ephakathi Ephakathi
• I-GCC
• Israyeli
• Indawo yonke yaseMpumalanga Ephakathi
• Africa
• Iningizimu Afrika
• I-Afrika Emaphakathi
• ENyakatho Afrika

Amaphrofayili eNkampani

• Inkampani BioSenic SA
• Inkampani Mereo Biopharma Group PLC
• Inkampani CELGENE CORP
• U-Eli Lilly kanye nenkampani
• Inkampani Cipla Inc.
• I-Amgen Inc.
• ISun Pharmaceutical Industries Ltd.
• Inkampani Viatris Inc.
• Inkampani Teva Pharmaceutical Industries Ltd.
• Okuningi ngo-Merck & Co., Inc.
• Ukulinganisa kwenkampani Jubilant Pharmova Limited
• U-Aurobindo Pharma
• Inkampani Ultragenyx Pharmaceutical Inc.
• Inkampani ye-OrthoPediatrics Corp.

BlogInnovazione.it